Charity Registration Number 1121784
Company Registration Number 06249601 (England and Wales)
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
(COMPANY LIMITED BY GUARANTEE)
TRUSTEES, REPORT AND UNAUDITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
GHARITY GofiifyAlJSION
FIRST CONTACT
06 JAN2
RECEIVED

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
CONTENTS
Page
Legal and administrative information
Trustees. report
Statement of trustees, responsibilities
Independent Examinerfs Report
Statement of financial activities
Balan¢e sheet
10
Notes to the accounts
11-16

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
LEGAL AND ADMINISTRATIVE INFORMATION
Trustees
A Budgeo..
K Hill
K Stubbs
R Hancock
D Small
Secrelary
A Budgen
Charity number
1121784
Company number
06249601
Prlnciple address
Riverside East
2 Millsands
Sheffield
S3 8DT
Registered office
RIVe￿ide East
2 Millsands
Sheffield
S3 8DT
Accountants
Landin Wilcock & Co
68 Queen Street
Sheffield
SI 1WR
Bankers
CAF Bank
25 Kings Hill Avenue
lQngs Hill
West Malling
Kent
ME194TA
HSBC
22, The Moor
Sheffield
S14PA

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
TRUSTEES. REPORT
FOR THE YEAR ENDED 30 JUNE 2024
The trustees. who are also Ihe directors of the charity for the purposes of the Companies Act, submit their annual
report and the unaudited financial statements of the June Hancock Mesothelioma Research Fund for the year
ended 30 June 2024. Reference and adminislrattve infomiation set out on page 1 form part of this report. The
"trustees confimi that th.ese financial statements comply with current slalut.ory requiremen.ts. in th.at they have
complied with the Charities Act 2011. the Companies Act 2006, the Memorandum and Articles of Association and
Accounting and Reporting by Charities= Statement of Recommended Practise applicable to chartties preparing
their accounts in accordan￿ wf(h the Financial Reporting Standard applicable in the UK and Republic of Ireland
(FRS102) (effective 1 January 2019).
Structure. governance and management
The June Hancock Mesothelioma Research Fund is a registered charity {charity number 1121784) and a company
limited by guarantee (company number 06249601). The charity's only voting members are its charity Irustees. It is
currently managed by a committee of fNe who undertake all day lo day lasks associated wtlh running the charity
and delivering its objedive5. No paid staff are employed.
Goveming documents
The charity was incorporated on 16th May 2007 and is govemed by its Memorandum and Artides of Assoaation.
This report covers the accounting period for the year ended 30th June 2024.
Recruitment of trustees
The trustees meet regularly to discuss the chartty's progress and formulate general policy. They are ultimately
responsible for the day-to-day management of the charity. including the making, enforcing and altering of rules,
and the authority for all expenditure. Trustees are elected andlor re-elecled in accordance with the provisions set
out in the organisation's constitution. The current operational management of the charity is conducted by the
Trustees together with the help of several volunteers under the guidance of the trustees.
All decisions of a management nature are rrode by the board of trnstees. the quotum is fity percent.
The income and property of the charity shall be applied solely towards the promotion of its objects as set forth in
the Memorandum of Association. No portion Ihereof shall be paid or transferred, directly or indirectly. by way of
bonus or otherwise by way of profrt. to members of the charity. No member of the board of trustees shall be
appointed to any office of the charity paid by way of salary or fees. Neither shall they receive any remuneration or
other benefit in money or kind from the charity.
The trustees, (who are also the direclors for the purposes of company law), who served during the year were:
A Budgen
K Hill
K Stubbs
R Hancock
D Small
None of tre trustees has any beneficial interest in the compary. All of the tTUStee5 are members of the company
and guarantee to contribute £1 in the event of a winding up.
New trustees are appointed by a resolution of the existing trustees, and there is no requirement for trustees to
retire annually and seek re-appointment. New Irustees undertake an induction and training process that includes
an inteNiew with the exisling trustees at which stage they are given a presenlation of the charity's objectives and
activities. They will also be provided with a bible of documents that includes strategy information, financial
accounts, truslee minutes. publicity materials, key project inf0m￿tIOn and Charity Commission information about
the responsibilities of Charity Trustees.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
Rlsk assessment
The trustees have assessed the maior risks to which the chaiity is exposed and are Satisfied that systems are in
.p.lace to miti.9ate exposure to these risks. Tbe major risk to the charty is considered to be its reliance.on
donations and fund raising from the general public. A significant reduction in income would limit the development
of the charity and the achievement of its objecb'ves.
Objectives and activities
The objectives of the charity as described in tts Memorandum are-
Promoting research into the prevention, treatment, alleviation and cJJre of mesothelioma and other asbestos
related conditions-
Disseminating infomiation about the said conditions (including bul not limiled lo. the results of research funded
by the JHMRF) for the benefit of the public provided that the objecttves shall always be wholly and exclusively
Charitable.
The main policies undertaken through the financial year in furtherance of these objectives were..
Accepting donations from those Vlllshing to raise money specffically for research inlo mesolhelioma. People
who have encountered the disease in themselves or loved ones can take comfort from the knowledge that the
money raised will fund research to help sufferer5 of the disease now and in the future.
Providing high qualty. easy to understsnd and up to date infortrration on ￿E$othe110Ma in publications and on
our website. This includes infomiation aboul the disease ttself. treatments, clinical trials, novel therapies,
where to go for more help, and also detsils of regional asbestos support groups.
Supporting events like Action Mesothelioma Oay to prowde infomation to patients and carers, promote a
better understsnding of mesothelioma and raise awareness of the health implications of asbestos and
asbestos products.
Inviting applications for high quality mesothelioma research propcts in the UK. All applications are
independently reviewed and assessed by a panel of experts.
Public benefit
We remain confident that we demonstrate properfy the public benefit expected by the Charity Commission in the
way that our objectives slate above. The above objectives and activrties are dearfy of value to mesothelioma
patients and their carers. famity and friends.
The trustees confirm that they have complied wilh the requirements of Section 4 of the Charities Act 2011 to have
due regard lo the public benefit guidance published by the Chartty Commission for England and Wales.
Use of volunteers
There are no volunteers used in the daily duties of the Charity, however. there are a number of academics and
clinicians who volunteer lo assist with the peer review process for new grant and fellowship applications, and
interirn and final reports submitted by existing grant holders.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
Grant award policy
The JHMRF runs a competitive award process vA)en sufficient funds are available. Applications are invited in
open, structured calls for high quality mesothelioma research projects. Health care professionals, post-do¢toral
scientists and other suitably qualified applicant5 are invited to apply for awards. Work must be carried out at a
-rèsearch" Instilution In Ihe UK". "Research projecls in basic science. translational fesearch "or applied -heallli are"
considered but the primary focus must be mesotheliorna.
The JHMRF funds major projects (up to £300,000), pumppriming grants (up to £25.000} and doctoral fellowships.
A number of travel grants to attend scienlrfic conferences or training courses are also available up to a maximum
of £500. All applications received by the deadline are peer-reviewed by at least three independent expert
referees, in accordan￿ with AMRC guidelines. Our network of contscts provides a source of volunteer peer
reviewers with specific medical and Scientif￿ expertise in a wide-range of areas. Applications and reviews are
then scrutinised and prioritised by the JHMRF Scientific Advisory Group (SAG). The SAG comprises academics,
research scientists and clinicians. It is currently chaired by a JHMRF trustee with research experience.
ResearGh proposals are assessed against the following criterta:
Quality of the research
Importance of the research question(s)
Relevance of the work lo JHMRF research stralegy
Scienlffic potential of the research
Originality of the research
Ethicality and research governan￿ of the research
Sustainability of the research
Management of the overall project
Additionally, fellowship applications are assessed for quality and SUFtability of the candidate. the host institution
and the supervisor.
The review process generates a shortlist of prioritised applications, which is tsken, to the JHMRF Board of
Trustees. The Board makes the final decision on funding after consideration of the SAG'S recommendations.
Funding calls are advertised on the websites of organisations such as RD Info. The British Lung Foundation and
Mesothelioma UK and circulated to the mesothelioma research community via the distribulion lists of special
interest groups in the British Thoracic Oncology Group and the Bribsh Mesothelioma Interest Group.
Achievements and performance
Fund raising activities have not fully recovered post-pandemi¢ and this year the JHMRF has focused on
consolidating funds in preparation for another funding round to open in 2025. While sponsored events and direct
donations remain relativety low, the charity has been fortunate to receive a legacy and donations from our pather
organisations raised at Action Mesothelioma Day (AMD) and other fund raising events held during the year. Due to
increasing numbers of AMD events taking place in various locations across the county, the JHMRF trustees
decided to continue the policy of raising awareness of the Fund by attending meetings organised by other groups.
Trustees presented at AMD 2023 events run by patient support groups in Sheffield, Southamplon and Manchester.
Principal Sources of Funding
JHMRF'S principal source of funding is generous donations. mainly from people affected by the disease. It has not
engaged in any fundraising acttvities in the current year to 30 June 2024.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
Achlevements and perfonnance continued
The JHMRF relains its commilment to building research capacty in mesothelioma by offering travel grants to
support. attendance at relevant training meetings and conferences. In 2024 the JHMRF awarded travel grants to
three doctoral students from the Universities of Bradford. Liverpool and Sheffield Hallam to enable them to attend
the 16th International Mesothelioma Interest Group (IMIGI 2023 conference held in the Lille Grand Palais, Lille,
France. International conferences provide early career researchers with Ihe opportunity to present their own work
and network with other researchers to leam about new developments in mesothelioma research.
Their presentations included=
1. The role of Exportin-1 IXP01) within cisplatin resistsnt Malignant Pleural Mesothelioma and specifically the use
of Selinexor IKPT-330) a seleclive inhibitor of nuclear export which is currenly used to treat haematological
cancers"
2. A breathomics-based approach to improve malignant mesothelioma diagnosis.,
3. Loss of BAP1 influences mesothelioma ￿llUlar motilty suggesting new therapeutic approaches.
Throughout the year, the JHMRF has conts'nued to work with extemal partners in the UK and Europe, including
the European Lung Foundation. Asbestos Victim Support Groups and Mesothelioma Patient Support Groups. The
JHMRF values these relationships to build a collaborative approach to mesothelioma research and drive
improvements in treatment and care for patients.
Financial revlew
The Fund ha5 continued to receive some extremely generous donations throughout the year. Donations come
mainly from people affected by the disease.
The level and number of awards that will be offered in the future will ￿e￿$sarilY be determined by the availability
and sustainability of funding. Funds wll be set aside to support annual applications for pilot and feasibility studies,
and for travel and educational awards. The next call for a major project award will be announced in due course.
Reserves policy
The current level of reserves stands at £278.667. It 15 the policy of the charity to mainlain unrestricted funds,
which are the free reserves of the charity, the minimum level of reserves is £10,000. This provides sufficient funds
to cover management, administration and support costs. Funds above this level will be available for the chartty lo
support other projects in the future.
Financial Instruments
Objectives and policies
The Charity's activities expose il to a number of financial risks including credtt risk and liquidity risk. The use of
financial derivatives is govemed by the charty5 policies approved by the board of trustees, which provide written
principles on the use of financial derivatives to manage these risks. The Charity does not use derivative financial
instrLtments for speculative purposes.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
TRUSTEES, REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
Flnanclal Instruments - continued
Credit Risk
The Charty's principal-. financial assets are-bank"""balances and"" cash- ""tra"de and ' othér re￿Illab.Ies. and
investments.
The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks
with high credit-ratings assigned by intemational credit-rating agencies.
The Charity has no significant C￿dit risk.
Liquidity risk
In order to maintain liquidity lo ensure that sufficient funds are available for ongoing operation5 and future
developments, the Chartty uses a mixlure of long-tem and short-temi debt finance.
Further details regarding liquidity risk can be found in the statement of accounting policies in the financial
statements.
Plans for the future
The charity will continue to pursue rts main aim. which is to promote high qualty research into mesothelioma in
the UK. The JHMRF will WO￿ closety with the new Mesothelioma Research Network and other research partners
to build collaborations and develop ideas that have potential to lead to ￿81 advances in research and care for
mesothelioma. We will adopt a flexible approach to funding using small grants and training awards to support
innovats.ve areas of research and major project awards to progress ideas further.
The patient will remain at the heart of the JHMRF research strategy: mesothelioma is a disease with extremely
poor outcomes and limited treatment oplions. Improwng care for people with me50thelioma and increasing the
range of therapeutic options available to them is a priorTty area for the fund. We aim to achieve this by building a
strong and well-balanced portfolio of resea￿h, the outputs from which will be of real benefit to palients.
Mesothelioma is classed as an industrial disease and is caused by asbeslos exposure. The JHMRF will wort in
partnership with other organisations like the HSE and the International Ban Asbestos Secretsriat to raise
awareness of asbestos in order to reduce the risk of people contracting mesothelioma in the future. The JHMRF
will continue to support the call for a worldwide ban on the mining and manulacture of asbestos products, and
recognises the need to seek more sustainable methods of providing employment and shelter for vulnerable
populations in developing countries.
On behalf of the board of tnjstees
Adrian Budgen
Trustee
Dated." 22 November 2024
Dan Small
Trustee
Dated: 22 November 2024

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
STATEMENT OF TRUSTEES RESPONSIBILITIES
FOR THE YEAR ENDED 30 JUNE 2024
The trustees (who are also the directors of June Hancock Mesothelioma Research Fund for the purpose of
company law} are responsible for preparing the financial statements in accordance with the Uniled Kingdom
Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and
regulations.
Company law requires the trustees lo prepare financial statements for each financial year. Under company law the
trustees must not approve the financial ststements unless they are satisfied that they give a true and fair view of
the state of affairs of the charitable company and of its incoming reSoUr￿S and application of resour￿, including
its income and expenditure. for the period.
In preparing these accounts. the truslees are required to:
select suitable accounting policies and apply them consistenty:
observe the methods and principles in the Chartties SORP:
make judgements and estimates that are reasonable and prudent-
state whether applicable UK Accounting Standards have been followed, subject to any malerial departures
disclosed and explained in the financial statements..
prepare accounts on the going concem basis unles5 tt is inappropriate to presume Ihat the company will
continue in business.
The Iruslees are responsible for keeping proper accounting records which disclose ￿llth reasonable accuracy at
any lime the financial position of the charitable company and to enable them to ensure that the accounts comply
with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence
for taking reasonable steps for the prevention and detection of fraud and other irregularibes.
Approved by the trustees of the Charity on 22 November 2024 and signed on its behalf by:
Adrian Budgen
Trustee
Dan Small
Truslee

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF JUNE HANCOCK
MESOTHELIOMA RESEARCH FUND
FOR THE YEAR ENDED 30 JUNE 2024
I report on the accounts ofthe Charity forthe year ended 30 June 2024 vthich are set out on pages 9 to 16.
Your attention is to be drawn to the fact that the Charity has prepared the Financial Statements in accordance
with the financial Reportlng Standard applicable in the UK and Republic of Ireland (FRS 102) in preferènce lu
Ihe Accounling and Reporting by Charities.. Slalement of Recommended practi￿ issued on 1 April 2005 which is
referred to in the extant regulations but has since been withdrawn.
l understand that this has been done in order for the accounts to provrde a true and fair view in accordance with
the Generally Accepted Accounting Praclice effective for reporting periods beginning on or after 1 January 2019.
Respective responsibilities of trustees and examlner
The trustees (who are also the directors of the cornpany for the purposes of company law) are responsible for the
preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2)
of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.
Having satisfied myself Ihat the charity is not subject lo audit under company law and is eligible for independent
examination. il is my responsibility to..
examine the accounts under section 145 of the 2011 Act.,
to follow the procedures laid down in the general Directions given by the Charity Commission under section
145(5}(b) of the 2011 Act.. and
to state whether parttcular matters have come to my attention.
Basis of independent examlnerfs report
My examination was canied out in accordance with the general Directions given by the Charity Commission. An
examination includes a rewew of the accounting records kept by the Charity and a comparison of the accounts
presented with those records. It also includes consideration of any unusual items or disclosures in the accounts,
and seeking explanations from you as trustees conceming any such matters. The procedures undertaken do not
provide all the eviden￿ that would be required in an audit and consequently no opinion is given as to whether
the accounts present a 'true and fair view, and the report is limiied to those matters set out in the statement
Independent examinerfs ststement
In connection with my examination. no matter has come to ry attention..
(11 which gives me a reasonable cause to believe that in any material respect the requirements..
to keep accounting records in accordance with section 386 of Ihe Companies Act 2006= and
to prepare accounts which accord with accounting records. comply with the accounting requirements of
seclion 396 of the Companies Act 2006 and wth the methods and principles of the statement of
Recommended Practice: Accounting and Reporting by Charities have not been met., or
(21 to which. in my opinion, attention should be drawn in order to enable a proper understanding of the
accounts to be reached.
Tom Henshaw ACA
Landin Wilcock & Co
Chartered Accountants & Registered Auditors
68 Queen Street
Sheffield
S1 1WR

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 30 JUNE 2024
Unrestrf¢ted
funds
2024
Total
2023
Total
Notes
Income and Endowments from:
Income from Investments
Income from donations and legacies
13,649
35,450
13,649
35,450
6,146
40,274
Total income and endowments
49.099
49.099
46,420
Ex
enditure on:
Charltable actlvity
1,908
1,908
5,496
Research Grants & Costs
1,259
1,259
597,580
Net galns on Investsments
11
15,028)
(5,028)
1,052
Total resources expended
(1,861)
604,128
Net incomel(expenditure)
50.960
50.960
(557,7081
Transfer5 be￿een funds
10
Net movement in funds
50.960
50,960
{557,708)
Total funds brought forward
227,707
227.707
785,415
Total funds carried forward
13
278.667
278,667
227.707
The results for the year derive from continuing activities and there were no income. resources expended or
transfers with any Designated or Restricted Funds during the current or preceding financial period.
The statement of financial activities also complies with the requirements for an income and expenditure account
under the Companies Act 2006.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
UNAUDITED BALANCE SHEET
AS AT30 JUNE 2024
As reststed
2023
2024
Notes
Current assets
Investments
Other debtors
Cash at bank and in hand
11
183.164
1,105
345,434
173,814
882
569,730
529,703
744,426
Llabllitles
Creditors.. amounts falling due within
one year
Research Grant5
12
1.260
178.189
1.032
215,911
(179,449)
(216,943)
Total assets less current liabilities
350.254
527,483
Creditors due after more than one
year. Research Grants
171.587)
(299,776)
Net Assets
278.667
227.707
Income funds
Unrestricted funds
278,667
227,707
Accumulated funds
13
278,667
227,707
The company is entitled to exemption from audrt under Section 477 Companies Act 2006 for the year ended 30
June 2024.
The members have not required the company to obtain an audit of its financial statements for the year ended 30
June 2024 in accordance with Section 476 of the Cofflpanies Act 2006.
The directors acknowledge their responsibility for complying with the requirements of the Act with respect to
accounting records and for the preparation of accounts.
These accounts have been p￿pared in accordan￿ with the provisions applicable to companies subject to the
small companies, regime.
The accounts were approved by the board on 22 November 2024 and were signed by..
Adrian Budgen
Trustee
Dan Small
Trustee
10-

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 30 JUNE 2024
1 Accounting policles
1.1 Summary of significant accountlng policies and key accounting estlmates
.'The principal accounling policies applied in the preparation of these financkql statements. aretset. out-.
below. These policies have been consistendy applied to all the years presented, unless otherwise
stated.
1.2 Statement of compliance
The financial statements have been p￿pared in accordance ￿th Accounting and Reporting by
Charities.. Statement of Recommended Practi￿ applicable to charities preparing their accounts in
accordance with the Financial Reporttng Standard applicable in the UK and Republic of Ireland (FRS
102) (effective 1 January 2019) - {Charrties SORP (FRS 102)). the Companies Act 2006 and the
Charities Act 2011.
1.3 Basis of preparation
June Hancock Mesolhelioma Research Fund meets Ihe definition of a public benefit entity under FRS
102. Assets and liabilities are initially recognised at historical cost or Iransaclion value unless
othe￿iSe stated in the relevant accounting policy notes.
The presentation and functional currency is considered to be pound5 Sterling because this is the
urrency in the primary economic environment in which the Charity operates.
The prior year comparatives have been reststed to reflect the following adjuslmenl:
Fixed term cash deposits which mature over 6 months after the year end have been reclassified wtthin
current asset inveslments.
1.4 Going concern
The trustees consider that there are no material uncertainties about the Charity's ability to continue as
a going concem nor any significant areas of uncertanty that affect the canying value of assets held by
the charty.
1.5 Summary of disclosure exemptions
The Charity has opted to adopt Bullelin 1 published on 2 February 2016 and have therefore not
included a cash flow statement in these financial statements.
1.6 Fund accounting policy
Restricted funds are subject to specific conditions by donors as to how they may be used.
Unrestricted funds comprise funds thal have been donated or generated through charitable activities
which are not subject to any such usage conditions.
Designated fund5 are those either set aside by the trustees for specific purposes, or funds which are
treated as such in order to follow accounting trealment gurdelines as detailed within the Charities
SORP IFRS 102) and the 2011 Charities Act.
Further details of each fund are disdosed in note 13.
1.7 Incoming and endowments
Donations, legacies and other fomis of voluntary income are recognised as incoming resources when
there is entitlement, certainty of receipt. except insofar as they are incapable of financial measurement.
Investment income
Investment income is recognised on a re￿1vable basis.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
1.8 Resources expended
Resources expended are included in the Statement of Financial Aclivilies on an accruals basis, inclusive of
any VAT which cannot be recovered.
Expenditure which is dire¢tly attributable to charitable activities has been induded in this cost category.
Govemance costs are those incJJrred in the management and operation of the chartty's projects and
Charitable activities, together with any Cornplian￿ cosls.
1.9 Taxation
The Charity is considered to pass the test set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and
therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the
Charity is potenlially exempt from taxalion in respect of income or capital gains received within categories
covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of
Chargeable Gains Act 1992, to the extent that such incorne or gains are applied exclusively to charitable
purpose5.
1.10 Cash and Cash Equivalents
Cash and cash equivalents compllse cash on hand and call deposits, and other short-temi highly liquid
investments that are readily converb'ble to a known amount of cash and are subject lo an insignificant risk
of change in value.
1.11 Financial Instrurnents
Classification..
Financial assets and financial liabilities are recognised when the charity becomes a paty to the contractual
prowsions of the instrument.
Financial liabilities and equity instruments are classified according to the substance of the contractual
arrangements entered into. An equity instrument is any contract that evidences a residual interest in the
assets of the Charity after deducting all of its liabilities.
Recognition and measurement:
All financial assets and liabilities are inttialty measured at fair value, except for those financial assets
classified as at fair value through income or expenditure, which are initially measured at fair value (which 45
normally the transaction price excluding transaction costs), unless the arrangements constitutes a
financing transaction.
If an arrangement constitutes a financing transaction. the financial asset or financial liability is measured at
the present value of the future pay￿ntS discounted at a market rate of interest for a similar debt
instrument.
Financial assets and liabilities a￿ only offset in the statement of financial position when, and only when
there exists a legalty enforceable right to set off the recognised amounts and the Charity intends either to
setue on a net basis. or to realise the asset and settle the liability simultaneously.
Financial assets are derecognised when and only when
a) the contractual rights lo the cash flows from the financial asset expire or are settled,
b) the Charity transfers to another paty substantially all of the rtsks and rewards of ownership of the
financial asset, or
c) the Charity. despite having retsined some, but not all, s￿nIficant risks and rewards of ownership, has
transferred control of the asset to another party.
Financial liabilities are derecognised onty vthen the obligation specified in the contract is discharged,
cancelled or expires.
12-

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
2 Investment income
UK bank interest receivable
13,649
6,146
3 Incomlng from donations and legacies
2024
2023
Donations receivable
35,450
40,274
4 Charitable actlvity costs
2024
2023
Fundraising and event expenditure
3,788
Governan￿ costs
1,908
1,708
1,908
5,496
5 Govemance costs
2024
2023
Accountancy & Professional fees
Bank charges
mis￿11aneouS expenses
1.437
351
120
1,121
480
107
1,908
1,708
13-

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
6 Research Grants
2024,". YI**• 2023
Awarded in year.
Projects and research fellowships
Charge in SOFA
Paid in the year
Movemenl
1,259
1,259
(267.170)
(265,911)
597,580
597,580
(97,189
500,391
Balance al start of year
515,687
15,296
Balance at end of year
249.776
515,687
Due within one year
Due after more than one year
178.189
71,587
215,911
299.776
Balance at end of year
249.776
515,687
Grants awarded during the year.
JHMRF awarded travel grants to three doctoral students from the Universitie5 of Bradford, Liverpool and
Sheffield Hallam to enable them to attend the 16th Intemational Mesothelioma Interest Group (IMIG)
2023 Conferen￿ held in the Lille Grand Palais. Lille, France.
7 Trustees
No acting trustees (or any persons connected with them) received any remuneration during the year. No
trustee travel expenses were reimbursed to Trustees during the year. (2023.. £Nil).
8 Employees
Other than the trustees, the company had no employees.
9 Taxation
The Charity is a registered tharity and is therefore exempt from taxation.
10 Transfers
There was no income or resour￿$ expended by way of any Designated or Restricted Funds, hen￿ there
were no transfers between funds during the period.
14-

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
11 Investments
As restated
2023
2024
Quoted Invéstments & Long Tèmi Deposits
Balance al start of year
173,814
174,321
Additions in the year
4.321
545
Movement in valuation of investment
5,029
(1,0521
Balance at end of year
183,164
173,814
Investments includes an investment bond and two fvielve nK)nth deposit accounts. At 30 June 2024 the
market value of the bond was £64,240 and the amounts held on deposit total £118,924.
12 Creditors.. amounts falling due within one year
2024
2023
Accruals
1,260
1,032
13 Analysis of net assets between funds
Unrestrlcted
funds
2024
Total
2023
Total
Fund balances at 30 June 2023 are
represented by..
Tangible fixed assets
Current assets
529.703
529,703
744,426
Creditor5'. amounts falling due within
one year
(179.449)
(179,H9)
(216,943}
Credilors.. amounts falling due after
more than one year
(71.587)
(71,587)
(299,7761
278.667
278,667
227,707
14 Contingent liabilities
There were no contingent liabilities as at 30 June 2024.
15-

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
15 Capltsl comrnitments
There were no capital commitments as at 30 June 2024.
16 Post balance sheet events
There are no events after the balance sheet date which the trustees feel should be brought to the
attention of the members.
17 Related Party Transactions
There have been no related party transaclions in the reporting period that require disclosure.